Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]PDE4B-13 is a novel fluorine-18 labeled positron emission tomography (PET) tracer designed for the in vivo imaging of phosphodiesterase 4B (PDE4B) in the brain. Developed by researchers at Jinan University and Emory University, the tracer is optimized for high-affinity, specific binding to PDE4B, which is a key regulator of intracellular cAMP signaling implicated in neuroinflammation and neurodegenerative disorders such as Parkinson's disease. Preclinical evaluations in rodent and non-human primate models have demonstrated favorable brain kinetics, high brain uptake, and region-specific distribution, supporting its potential as a quantitative imaging tool for monitoring PDE4B expression and neuroinflammatory dynamics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]PDE4B-13.